Generally, METABRIC dataset analysis showed a negative correlation of Fbln2 with luminal markers (Krt18, Krt19, Ddr1, and Krt8) [37–40], and a positive correlation with myoepithelial cell markers (Krt14, Itgb1, ITtga3, Krt7, Krt5, Krt17, and Krt14) [37–40] and mesenchymal markers (Fn, Vim, Cdh2, and Cdh11) [45] in the majority of the molecular and clinical subtypes of breast cancer patients [including grouping based on hormonal receptors, LN status, tumor grade, growth factor receptor status, and tumor proliferation] (Fig. 4a). This evidence concerns the gene KRT5 and neoplasm.